---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-032628"
form_type: "8-K"
ticker: "ACUT"
cik: "0001850767"
company_name: "Accustem Sciences Inc."
filed_at: "2022-11-16T23:59:59+00:00"
generated_at: "2026-06-21T17:45:10.240668+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# AccuStem Sciences appoints Sean McDonald as independent director; board now five members

## Summary
- Sean McDonald appointed to AccuStem board effective Nov. 14, 2022; board expanded from four to five members.
- McDonald currently CEO of Ocugenix, a therapeutics company focusing on ocular diseases.
- He previously scaled Automated Healthcare (acquired by McKesson) and served as CEO of Precision Therapeutics.
- McDonald was a director at Respironics before its $5.1B acquisition by Philips.

## SEC filing metadata
- accession: 0001493152-22-032628
- form_type: 8-K
- ticker: ACUT
- cik: 0001850767
- company_name: Accustem Sciences Inc.
- filed_at: 2022-11-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850767/000149315222032628/0001493152-22-032628-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850767/000149315222032628/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-032628
- JSON: https://secwatch.observer/filing/0001493152-22-032628.json
- Plain text: https://secwatch.observer/filing/0001493152-22-032628.txt

## Key facts
- Executive change
  Sean McDonald was elected as independent director at Accustem Sciences Inc..
  - Action: elected
  - Role: independent director
  source text: On November 14, 2022, the Board of Directors (the “Board”) of AccuStem Sciences, Inc. (the “Company”) increased the size of the Board to five members and elected Sean McDonald as an independent director, for a term continuing to the Company’s next annual meeting of shareholders, when all directors will be subject to election by shareholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850767/000149315222032628/0001493152-22-032628-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.